GILD
AR$24,475.00
▲+0.31%
Stock
Gilead Sciences, Inc.
Official Company Name: Gilead Sciences, Inc.
Stock Symbol: GILD
Stock Market: Buenos Aires Stock Exchange - BCBA
Currency: Argentine peso - ARS
GILD Stock Price - 1 Year Price Evolution & Moving Averages
1 Year Return
▲+51.84%
Daily closing prices, with moving averages and volumes - Argentine peso (ARS)
Moving averages:
- — EMA20
- — SMA50
- — SMA200
Gilead Sciences, Inc. Categories
United States
languages
Healthcare
languages
Drug Manufacturers—General
Healthcare
Drug Manufacturers—General
Company Description
Gilead Sciences, Inc., is a pharmaceutical and biotechnology company focusing on antiviral drugs to treat HIV, hepatitis B, hepatitis C, and influenza, notably producing and commercializing the blockbuster drugs Harvoni and Sovald. Besides, Gilead conducts research to develop a pipeline of new drugs and treatments and it also considers the acquisition of other blockbuster drugs.
GILD Stock Data
| Open | AR$24,250.00 |
| High | AR$24,650.00 |
| Low | AR$24,250.00 |
| Close | AR$24,475.00 |
| Volume | 160 |
| Previous Close | AR$24,400.00 |
| 1-Day Change | 75.00 |
| 1-Year Change | 8356.00 |
| Average Daily Volume | 833 |
| 52-Week High | AR$28,370.00 |
| 52-Week Low | AR$15,485.00 |
Disclaimer
All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!
Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.
Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).
Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.
Please conduct your own due diligence to verify insights.